Granules India Limited (BSE: 532482, NSE: GRANULES) today announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. Senn develops and manufactures, Peptides and Peptides based applications for its global customers, providing contract research, development, and manufacturing services.

印度格兰ules有限公司（孟买证券交易所代码：532482，国家证券交易所代码：GRANULES）今天宣布签署了关于收购瑞士CDMO公司Senn Chemicals AG的协议，该公司专注于多肽领域。Senn为全球客户开发和生产多肽及基于多肽的应用，提供合同研究、开发和制造服务。

The closing of the acquisition is subject to certain conditions. The closing is expected to occur in the first half of 2025..

收购的完成取决于某些条件。预计将在2025年上半年完成。

The acquisition brings Senn’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship, including innovators and brand owners across Pharma, Cosmetics, Amino Acid Derivatives (AAD) & theragnostic segments..

此次收购带来了Senn在液相肽合成（LPPS）和固相肽合成（SPPS）方面的专业知识，以及强大的CDMO业务和已建立的客户关系，包括制药、化妆品、氨基酸衍生物（AAD）及治疗诊断领域的创新者和品牌拥有者。

Senn’s manufacturing facility is certified under ISO 9001:2015 and is regularly inspected and approved for cGMP production by Swissmedic. Under the Mutual Recognition Agreement (MRA) between Swissmedic and the U.S. Food and Drug Administration (FDA), cGMP inspections conducted by Swissmedic are recognized by the FDA..

Senn的生产设施通过了ISO 9001:2015认证，并定期接受瑞士药品监督管理局（Swissmedic）的检查并获得cGMP生产批准。根据瑞士药品监督管理局（Swissmedic）与美国食品药品监督管理局（FDA）之间的相互认可协议（MRA），由Swissmedic进行的cGMP检查得到FDA的认可。

This acquisition enables Granules’ acquiring capabilities into high-growth peptide- based therapeutics. The acquisition aligns with Granules’ vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including GLP-1 receptor agonists and other next-generation therapeutics.

此次收购使Granules具备了进入高增长肽类治疗领域的能力。该收购符合Granules进入快速扩展的基于肽类的抗糖尿病和抗肥胖市场（包括GLP-1受体激动剂和其他下一代治疗药物）的愿景。

Granules and Senn have been developing two GLP-1 based APIs, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn’s R&D capabilities..

Granules和Senn一直在开发两种基于GLP-1的原料药，这两个项目进展顺利，并计划在产品组合中增加更多的基于肽的原料药，利用Senn的研发能力进行开发。

The acquisition marks Granules foray into CDMO segments, leveraging Senn’s existing CDMO business and customer relationships, on back of its R&D and manufacturing platform. With this transaction, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics.

此次收购标志着Granules进军CDMO领域，利用Senn现有的CDMO业务和客户关系，依托其研发和制造平台。通过此次交易，Granules将利用Senn在欧洲的影响力及其创新驱动的多肽平台，加速其CDMO扩展，并满足氨基酸衍生物（AAD）、多肽片段和多肽类治疗药物快速增长的需求。

Senn presence in Europe, provides access to a skilled R&D talent pool and regulated market clients, further strengthening Granules’ global footprint..

森在欧洲的存在，提供了获取熟练的研发人才库和受监管市场客户的机会，进一步增强了Granules的全球足迹。

By integrating Senn’s capabilities with Granules’ expertise in large-scale, cost-efficient manufacturing, Granules aim to become a key player in development and manufacturing of peptide-based applications across Pharmaceuticals, cosmetics and theragnostic segments industries, spanning the entire value chain from AADs and Peptide fragments to peptide-based active ingredients..

通过将Senn的能力与Granules在大规模、成本效益制造方面的专业知识相结合，Granules旨在成为制药、化妆品和治疗诊断领域中基于肽的应用开发和制造的关键参与者，横跨从AAD和肽片段到基于肽的活性成分的整个价值链。

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, said

印度格兰ules公司董事长兼董事总经理克里希纳·普拉萨德·奇古鲁帕蒂博士说

“The

“

acquisition

收购

of

的

Senn

森恩

Chemicals

化学品

AG

银屑病关节炎

marks

标记

a

a

significant

重要的

milestone

里程碑

in

在

Granules’ strategic

颗粒战略

growth

增长

journey.

旅程。

By

通过

entering

进入

the

的

rapidly

迅速地

growing

成长

peptide

肽

therapeutics

治疗学

segment

段

and acquiring CDMO capabilities, we are expanding into next-generation therapeutics that align with our commitment to innovation and affordability. Senn’s expertise in peptide synthesis, coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality peptide-based solutions globally.

通过获取CDMO能力，我们正在扩展到与我们创新和可负担性承诺相符的下一代疗法。Senn在肽合成方面的专业知识，加上我们大规模、高成本效益的制造能力，使我们能够在全球范围内提供高质量的基于肽的解决方案。

This acquisition is a pivotal moment in our vision to transform Granules to a science and innovation led organization and become a trusted partner in complex and specialized therapeutics.”.

此次收购是我们将颗粒物转变为以科学和创新为主导的组织，并成为复杂和专业治疗领域值得信赖的合作伙伴这一愿景的关键时刻。

Dr. Rico Wiedenbruch, Chairman, Senn Chemicals AG, said

塞恩化学公司董事长里科·维登布鲁赫博士说

“We are excited to join forces with Granules India, a company that shares our commitment to scientific excellence and customer-centric innovation. With Granules’ scale, operational efficiency, and global reach in pharmaceuticals industry, we see strategic fit and tremendous potential to accelerate our growth and expand our capabilities in rapidly growing peptide therapeutics.

“我们很高兴与印度Granules公司携手合作，这家公司与我们一样致力于科学卓越和以客户为中心的创新。凭借Granules在制药行业的规模、运营效率和全球影响力，我们看到了战略契合点以及加速我们成长和扩展我们在快速增长的多肽治疗领域能力的巨大潜力。”

This partnership strengthens our ability to serve our customers with best-in-class CDMO solutions while driving innovation in peptide development and manufacturing.”.

这一合作增强了我们为客户提供一流的CDMO解决方案的能力，同时推动了肽类开发和制造的创新。

Advisors

顾问

Stifel Nicolaus India served as the exclusive financial advisor to Granules India on the transaction. Loyens & Loeff acted as legal advisor, Deloitte as financial and tax advisor, providing financial and tax due diligence services, and Kroll provided valuation advisory services for the transaction.

Stifel Nicolaus India 担任了此次交易中Granules India的独家财务顾问。Loyens & Loeff 担任法律顾问，Deloitte 担任财务和税务顾问，提供财务和税务尽职调查服务，Kroll 为此次交易提供了估值咨询服务。